Skip to main content

Table 2 Characteristics of 72 patients according to the respectability classification

From: Neoadjuvant chemotherapy followed by curative-intent surgery for perihilar cholangiocarcinoma based on its anatomical resectability classification and lymph node status

FactorsR (n = 29)BR (n = 23)LA (n = 20)p value
Age (years)72 (44–87)70 (51–80)70 (45–85)0.725
Gender (male / female)15 / 1412 / 1116 / 40.094
Patients with biliary drainage (%)25 (86.2%)16 (69.6%)17 (85.0%)0.270
Initial blood examination
 Neutrophil-to-lymphocyte ratio (NLR)2.03 (0.97–8.15)2.21 (1.14–7.90)3.15 (0.98–10.59)0.083
 Prognostic nuritional index (PNI)42.5 (33.9–55.6)44.6 (35.2–56.2)42.4 (32.7–54.8)0.566
 CEA (mg/dl)3.6 (0.7–38.4)3.6 (0.9–16.3)4.1 (1.6–65.7)0.625
  CA19–9 (U/ml)100.7 (7.0–7898)98.4 (1.0–9066)208 (5.2–5265)0.889
Initial clinical staging
 Patients with cT4 (%)2 (6.9%)16 (69.6%)17 (85.0%)< 0.001*
 Patients with clinical LN metastasis (%)7 (24.1%)7 (30.4%)10 (50.0%)0.158
Patients with neoadjuvant GS therapy (%)8 (27.6%)21 (91.3%)18 (90.0%)< 0.001*
 Completion rate of initial 2 cycles (%)7/8 (87.5%)20/21 (95.2%)16/18 (88.9%) 
  Median relative dose intensity of S-1 (%)100%100%100% 
  Median relative dose intensity of G (%)101%87.4%81.8% 
 Patients with adverse events (%)7 (87.5%)14 (66.7%)14 (77.8%) 
  Toxicity grade 1/2426 
  Toxicity grade 3/4 (grade 3 cholangitis)3 (2)12 (10)8 (6) 
Patients with resection (%)26 (89.7%)17 (73.9%)6 (30.0%)< 0.001**
  1. R resectable, BR borderline resectable, LA locally advanced * R vs. BR, UR, **R, BR vs. UR
  2. CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, GS gemcitabine plus S-1, LN lymph node, G gemcitabine